drugset / Trial / NCT01902173
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase 1/2
Completed
27 enrolled
National Cancer Institute (NCI)
GlaxoSmithKline · collabNovartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with dabrafenib and trametinib may be a better treatment for cancer.
Timeline
- Start
- 2013-10-08
- Primary completion
- 2018-05-16
- Completion
- 2023-12-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabrafenib | Small molecule | 150 mg | Oral |
| Subject | Trametinib | Small molecule | 1.5 mg | Oral |
| Subject | Trametinib | Small molecule | 2 mg | Oral |
| Subject | Uprosertib | Small molecule | 25 mg | Oral |
| Subject | Uprosertib | Small molecule | 50 mg | Oral |
| Subject | Uprosertib | Small molecule | 75 mg | Oral |